How to buy VBI Vaccines shares | $3.41
Own VBI Vaccines shares in just a few minutes.
VBI Vaccines Inc is a biotechnology business with stocks listed in the US. VBI Vaccines shares (VBIV) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$3.41 – a decrease of 3.67% over the previous week.
How to buy shares in VBI Vaccines
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for VBI Vaccines. Find the share by name or ticker symbol: VBIV. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until VBI Vaccines reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$3.41, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of VBI Vaccines, depending on your broker.
- Check in on your investment. Congratulations, you own a part of VBI Vaccines. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- VBI Vaccines key stats
- Compare share trading platforms
- Is VBI Vaccines stock a buy or sell?
- VBI Vaccines performance over time
- Can I short VBI Vaccines shares?
- VBI Vaccines's financials
- How volatile are VBI Vaccines shares?
- Does VBI Vaccines pay a dividend?
- Have VBI Vaccines shares ever split?
- Other common questions
How has coronavirus impacted VBI Vaccines's share price?
Since the stock market crash in March caused by coronavirus, VBI Vaccines's share price has had significant positive movement.
Its last market close was US$3.41, which is 56.30% up on its pre-crash value of US$1.49 and 394.20% up on the lowest point reached during the March crash when the shares fell as low as US$0.69.
If you had bought US$1,000 worth of VBI Vaccines shares at the start of February 2020, those shares would have been worth US$533.09 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth US$2,507.34.
VBI Vaccines share priceUse our graph to track the performance of VBIV stocks over time.
VBI Vaccines shares at a glance
|Latest market close||USD$3.41|
|52-week range||USD$0.4655 - USD$6.93|
|50-day moving average||USD$3.7251|
|200-day moving average||USD$2.5662|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.758|
Standard brokerage - US shares
Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.
- $0 brokerage for US stocks
- Trades starting from $50
- Fractional shares
- Copy top traders
Important: Share trading carries risk of capital loss.
Compare share trading platforms
Is it a good time to buy VBI Vaccines stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
VBI Vaccines price performance over time
|1 week (2020-09-14)||-3.13%|
|1 month (2020-08-21)||-6.58%|
|3 months (2020-06-19)||17.99%|
|6 months (2020-03-20)||334.84%|
|1 year (2019-09-20)||575.25%|
|2 years (2018-09-21)||77.60%|
|3 years (2017-09-21)||-12.34%|
|5 years (2015-09-21)||1,613.57%|
VBI Vaccines financials
|Revenue TTM||US$1.8 million|
|Gross profit TTM||US$-5,683,000|
|Return on assets TTM||-17.03%|
|Return on equity TTM||-44.27%|
|Market capitalisation||US$827.7 million|
TTM: trailing 12 months
Shorting VBI Vaccines shares
There are currently 10.9 million VBI Vaccines shares held short by investors – that's known as VBI Vaccines's "short interest". This figure is 22.3% down from 14.0 million last month.
There are a few different ways that this level of interest in shorting VBI Vaccines shares can be evaluated.
VBI Vaccines's "short interest ratio" (SIR)
VBI Vaccines's "short interest ratio" (SIR) is the quantity of VBI Vaccines shares currently shorted divided by the average quantity of VBI Vaccines shares traded daily (recently around 12.1 million). VBI Vaccines's SIR currently stands at 0.9. In other words for every 100,000 VBI Vaccines shares traded daily on the market, roughly 900 shares are currently held short.
However VBI Vaccines's short interest can also be evaluated against the total number of VBI Vaccines shares, or, against the total number of tradable VBI Vaccines shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case VBI Vaccines's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 VBI Vaccines shares in existence, roughly 70 shares are currently held short) or 0.0934% of the tradable shares (for every 100,000 tradable VBI Vaccines shares, roughly 93 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against VBI Vaccines.
Find out more about how you can short VBI Vaccines stock.
VBI Vaccines share dividends
We're not expecting VBI Vaccines to pay a dividend over the next 12 months.
Have VBI Vaccines's shares ever split?
VBI Vaccines's shares were split on a 1:40 basis on 1 May 2016. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VBI Vaccines shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for VBI Vaccines shares which in turn could have impacted VBI Vaccines's share price.
VBI Vaccines share price volatility
Over the last 12 months, VBI Vaccines's shares have ranged in value from as little as US$0.4655 up to US$6.93. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VBI Vaccines's is 1.607. This would suggest that VBI Vaccines's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
VBI Vaccines overview
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for a functional cure of chronic hepatitis B. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the target virus to elicit a potent immune response. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. In addition, the company engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It primarily serves physicians and pharmacists through direct sales. VBI Vaccines Inc. has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. It also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.
Frequently asked questions
Ask an Expert